Pasithea Therapeutics Corp.
KTTA
$1.19
-$0.02-1.65%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 240.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 240.70K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.10M | 7.84M | 8.05M | 7.88M | 8.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.14M | 16.92M | 16.81M | 15.98M | 14.87M |
| Operating Income | -16.14M | -16.92M | -16.81M | -15.98M | -14.87M |
| Income Before Tax | -15.76M | -16.37M | -16.10M | -15.51M | -14.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.76 | -16.37 | -16.10 | -15.51 | -14.53 |
| Earnings from Discontinued Operations | -16.90K | -16.90K | -182.00K | -453.90K | -1.50M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.78M | -16.39M | -16.28M | -15.96M | -16.03M |
| EBIT | -16.14M | -16.92M | -16.81M | -15.98M | -14.87M |
| EBITDA | -15.49M | -16.28M | -16.16M | -15.33M | -14.38M |
| EPS Basic | -14.83 | -14.83 | -14.00 | -13.01 | -12.28 |
| Normalized Basic EPS | -9.25 | -9.25 | -8.65 | -7.90 | -6.47 |
| EPS Diluted | -14.83 | -14.83 | -14.00 | -13.01 | -12.28 |
| Normalized Diluted EPS | -9.25 | -9.25 | -8.65 | -7.90 | -6.47 |
| Average Basic Shares Outstanding | 4.36M | 4.57M | 4.83M | 5.09M | 5.13M |
| Average Diluted Shares Outstanding | 4.36M | 4.57M | 4.83M | 5.09M | 5.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
